-
Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals3/22/2024
AstraZeneca's $2.4 billion acquisition of Fusion Pharma is the third billion dollar radiopharmaceuticals deal in recent months. John Valliant, Fusion's founder and CEO, explains why alpha-emitters are better than beta-emitters, and why radiopharmaceuticals are poised for substantial growth.
-
Where Are They Now? Novo Nordisk3/18/2024
In a few short years, Novo Nordisk has gone from belt-tightening to parachute pants, and is now replaying a GLP-1 competition with Eli Lilly that kicked off with Victoza and Trulicity ten years ago.
-
A Proactive Approach To ‘Unscrupulous’ Patent Practices3/7/2024
Terran Biosciences aims to subvert a patent strategy some drugmakers have used to delay the entrance of generic competitors. The company is patenting its own psychedelic salts, polymorphs, and prodrugs, and targeting FDA's 505(b)(2) pathway.
-
NORD Expands Advocacy And Support For Rare Disease Patients, And Industry2/29/2024
NORD's president and CEO, Peter Saltonstall, offers details on the organization's current activities and ongoing work with biopharmaceutical companies developing rare disease drugs.
-
The Good And Bad Of Copromotion2/26/2024
Are two minds, or companies, better than one for drug commercialization? It depends on the details, says Eisai's Paul Hawthorne.
-
No Playbook For Leqembi: Eisai’s Long Game In Alzheimer’s Disease2/16/2024
Paul Hawthorne, Eisai's EVP, purpose and chief business officer, offers insight into building a market for Leqembi, Eisai's pricing and commercial strategy, and the challenges and opportunities in Alzheimer's disease.
-
Dynavax’s Evolving Business Model2/9/2024
Dynavax found a new revenue stream during COVID, and a way to grow market share in the absence of a market. Ryan Spencer describes the ups and downs, and his own journey to CEO role.
-
Where Are They Now? Ono Pharmaceuticals2/5/2024
Ono Pharmaceuticals continues its quest to become a global biopharmaceutical company, after discovering and helping to launch one of the most successful cancer drugs, Opdivo, in the last decade.
-
Innovation From Animals And Evolution2/1/2024
Insights gleaned from a variety of animal species, and a deeper understanding of evolution aided by artificial intelligence, could help bring a new wave of therapies to market.